

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**March 8, 2022**

**Date of Report (Date of earliest event reported)**



**HELIUS MEDICAL TECHNOLOGIES, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

**DELAWARE**  
**(State or Other Jurisdiction  
of Incorporation)**

**001-38445**  
**(Commission File Number)**

**36-4787690**  
**(IRS Employer  
Identification No.)**

**642 Newtown Yardley Road, Suite 100**  
**Newtown, PA**  
**(Address of Principal Executive Offices)**

**18940**  
**(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (215) 944-6100**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Class A Common Stock, \$0.001</b>	<b>HSDT</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of  
Item 5.02 Certain Officers.**

On March 8, 2022, Mr. Mitchell Tyler notified the Board of Directors (the “Board”) of Helius Medical Technologies, Inc. (the “Company”) of his intention to retire from service on the Board upon expiration of his current term, and therefore, that he will not stand for re-election to the Board at the Company’s 2022 annual meeting of stockholders. Mr. Tyler intends to continue to serve on the Board until immediately prior to such annual meeting. Mr. Tyler’s decision not to stand for re-election to the Board is not the result of any disagreement with the Company.

